Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
MEDIF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-0.01
vs -0.08
Q1.23
N/A
-0.02
vs -0.03
Q2.23
N/A
-0.01
vs -0.03
Q3.23
N/A
-0.01
vs -0.03
Q4.23
N/A
-0.01
vs -0.01
Q1.24
N/A
-0.01
vs -0.02
Q2.24
+100%
NA
vs -0.01
Q3.24
+100%
NA
vs -0.01
Q4.24
N/A
-0.00
vs -0.01
Q1.25
N/A
-0.01
vs -0.01
Sales Growth
YoY
Current
Estimates
Q1.23
+20%
5.8M vs 4.9M
Q2.23
+120%
9.6M vs 4.4M
Q3.23
+17%
8.5M vs 7.3M
Q4.23
+63%
9.1M vs 5.6M
Q1.24
+67%
9.8M vs 5.8M
Q2.24
+8%
10.3M vs 9.6M
Q3.24
+15%
9.8M vs 8.5M
Q4.24
+32%
12M vs 9.1M
Q1.25
+27%
12.4M vs 9.8M
Q2.25
+26%
13.1M vs 10.3M
Return on Equity
QoQ
Q1.23
-6%
-0.06
vs -0.10
Q2.23
-5%
-0.05
vs -0.06
Q3.23
-8%
-0.08
vs -0.05
Q4.23
-6%
-0.06
vs -0.08
Q1.24
-7%
-0.07
vs -0.06
Q2.24
-5%
-0.05
vs -0.07
Q3.24
-6%
-0.06
vs -0.05
Q4.24
-4%
-0.04
vs -0.06
Institutionnal Ownership
globenewswire.com
10 hours ago
globenewswire.com
11 hours ago
globenewswire.com
13 hours ago
globenewswire.com
17 hours ago
globenewswire.com
19 hours ago
Quote Panel
Key Metrics
Relative Strength
MEDIF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. It formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. The company also provides GMP flower sourcing, packaging, and distribution services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.
OTC
Unprofitable
Unprofitable
0.01 ( 9.71%)
Relative Strenght
Volume Buzz
-97%
Earning Acce
No
Dist 52w H.
29%Forecast
382%2025-Revenue
-262%2025-EPS
-3445%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available